Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP874945.RABfNRthBMPzDwbQFlqNVqh7sbgh6uSuAJz3AO1j6Ee5c130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP874945.RABfNRthBMPzDwbQFlqNVqh7sbgh6uSuAJz3AO1j6Ee5c130_assertion type Assertion NP874945.RABfNRthBMPzDwbQFlqNVqh7sbgh6uSuAJz3AO1j6Ee5c130_head.
- NP874945.RABfNRthBMPzDwbQFlqNVqh7sbgh6uSuAJz3AO1j6Ee5c130_assertion description "[The frequency of TAP1, LMP2 and tapasin loss varied between 33% of primary adenocarcinomas, 40% of HIN to approximately 67% of metastases.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP874945.RABfNRthBMPzDwbQFlqNVqh7sbgh6uSuAJz3AO1j6Ee5c130_provenance.
- NP874945.RABfNRthBMPzDwbQFlqNVqh7sbgh6uSuAJz3AO1j6Ee5c130_assertion evidence source_evidence_literature NP874945.RABfNRthBMPzDwbQFlqNVqh7sbgh6uSuAJz3AO1j6Ee5c130_provenance.
- NP874945.RABfNRthBMPzDwbQFlqNVqh7sbgh6uSuAJz3AO1j6Ee5c130_assertion SIO_000772 14750179 NP874945.RABfNRthBMPzDwbQFlqNVqh7sbgh6uSuAJz3AO1j6Ee5c130_provenance.
- NP874945.RABfNRthBMPzDwbQFlqNVqh7sbgh6uSuAJz3AO1j6Ee5c130_assertion wasDerivedFrom befree-20150227 NP874945.RABfNRthBMPzDwbQFlqNVqh7sbgh6uSuAJz3AO1j6Ee5c130_provenance.
- NP874945.RABfNRthBMPzDwbQFlqNVqh7sbgh6uSuAJz3AO1j6Ee5c130_assertion wasGeneratedBy ECO_0000203 NP874945.RABfNRthBMPzDwbQFlqNVqh7sbgh6uSuAJz3AO1j6Ee5c130_provenance.